Evidence map›Paper›PMID 41177175›Full record

ReviewJournal of inherited metabolic disease2025

Removal of Toxic Metabolites-Chelation: Manganese Disorders.

Hendrik Vogt, George E Kostakis, Rupert Purchase, John Spencer, Karin Tuschl

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of inherited metabolic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Removal of Toxic Metabolites-Chelation: Manganese Disorders.Journal of inherited metabolic disease · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hendrik VogtDepartment of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
George E KostakisDepartment of Chemistry, School of Life Sciences, University of Sussex, East Sussex, UK.
Rupert PurchaseDepartment of Chemistry, School of Life Sciences, University of Sussex, East Sussex, UK.
John SpencerDepartment of Chemistry, School of Life Sciences, University of Sussex, East Sussex, UK.
Karin TuschlDepartment of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID https://orcid.org/0000-0001-8599-8516

Funding

Medical Research Council MR/V006754/1
6 · The paper itself

Abstract

Manganese (Mn) overload is a characteristic of multiple disease entities, from acquired manganism upon environmental or occupational overexposure, to end-stage liver disease and certain genetic disorders. The latter include hypermanganesaemia with dystonia 1 and 2 caused by pathogenic variants in the genes encoding the Mn transporters SLC30A10 and SLC39A14. Excess Mn accumulates in the brain, particularly in the globus pallidus, leading to progressive dystonia-parkinsonism. Furthermore, Mn dyshomeostasis is a characteristic feature of common neurodegenerative disorders such as Parkinson's disease, whether as a cause or consequence needs to be determined, suggesting that Mn as an environmental toxicant may play a role in its aetiology. Therefore, there is a need for therapeutics that effectively chelate Mn and remove excess Mn from the brain. This review discusses the Mn chelators currently used in clinical practice, their advantages and disadvantages as well as their adverse effects. Na

Indexed as

Chelating AgentsManganeseManganese PoisoningAnimalsBrainCation Transport ProteinsHumansMetabolic DiseasesCation Transport ProteinsChelating AgentsManganesechelationcoordination chemistrymanganesemanganismSLC30A10SLC39A14

Identifiers

PMID41177175
PMCPMC12579993

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.